Research focused on lipid-lowering treatments has led to the development of new therapeutic options aimed at cardiovascular risk reduction. Gene silencing represents one of the most innovative approaches to reduce low-density lipoprotein cholesterol (LDL-C). Inclisiran is a small interfering RNA that inhibits proprotein convertase subtilisin/kexin type 9 synthesis and promotes LDL-C clearance by enhancing LDL-C receptor expression on hepatocyte cell surface. Several clinical studies have demonstrated inclisiran efficacy in terms of LDL-C reduction (~50%) with a dosage regimen of 300 mg administered twice a year after the first two doses administered at time 0 and after 90 days. Inclisiran use has recently been approved by the European and American drug regulatory agencies as a therapeutic option in addition to the maximum tolerated statin therapy in adults with primary hypercholesterolemia or mixed dyslipidemia who need further LDL-C reduction.
Reference: [ANMCO Position paper: Inclisiran: an innovative therapeutic approach for the clinical management of hypercholesterolemia].
Di Fusco SA, Scicchitano P, Spinelli A, Conte E, Aquilani S, Aiello A, Nardi F, Riccio C, Caldarola P, De Luca L, Roncon L, Valente S, Gulizia MM, Gabrielli D, Oliva F, Colivicchi F.
G Ital Cardiol (Rome). 2023 Jul;24(7):581-588.